Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158

NCT02101385 is registered in ClinicalTrials.gov with Bryan Schneider, MD as lead sponsor.

NCT NCT02101385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Lead sponsor
Bryan Schneider, MD
Phase
Phase 2
Overall status
Completed
Start date
April 3, 2014
Completion date
September 9, 2022
Enrollment
193 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, malignant neoplasm of breast